Posted by Michael Wonder on 02 Jul 2024
Pierre Fabre Laboratories announce granting of European marketing authorisation for Obgemsa (vibegron) in overactive bladder
28 June 2024 - The European Commission has authorised the marketing of Obgemsa (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients in Europe.
In 2022, Pierre Fabre Laboratories acquired the exclusive license for vibegron from Urovant Sciences for the registration and commercialszation of this innovative treatment in the European Economic Area.
